Beta Finch - S&P 100 - EN

Top 100 US-listed companies by market capitalization. AI-powered earnings call analysis for S&P 100 (SP100). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.

Beta Finch - S&P 100 - EN is a business podcast hosted by Unknown Host, with 0 episodes on record and a Required Pod Score of 83.

Unknown Host hosts Beta Finch - S&P 100 - EN, a business show with 0 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Beta Finch - S&P 100 - EN

  Costco Q4 2026 Earnings Analysis

  Sep 25, 20268 min

  More earnings analysis: https://betafinch.com Groups: RETAIL ( https://betafinch.com/groups/RETAIL) ────────── WELCOME TO BETA FINCH, YOUR AI-POWERED EARNINGS BREAKDOWN ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers straight from the source and translate them into something you can actually use. I'm Alex. JORDAN: And I'm Jordan. Today we're digging into Costco's fiscal fourth quarter and full-year 2026 results. ALEX: And before we get going, our standard reminder — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Okay, let's get into it, because there's a lot here. Costco just closed out fiscal 2026 with over 10% top-line sales growth for the year, and Q4 net sales came in at $93.87 billion — up 11.2% year over year. ALEX: And comparable sales were up 9.4% overall, 6.7% once you strip out gas price inflation and foreign exchange. That's actually been a pretty steady band for them — Gary Millerchip, the CFO, mentioned that 6-7% range has held for basically a full year now. JORDAN: Right, and net income was $2.998 billion, or $6.75 a share. But here's a wrinkle — that includes a one-time $0.15 per share benefit from IEEPA tariff refunds. Strip that out, and net income and EPS were still up a healthy 12.3% and 12.4% respectively. ALEX: The tariff refund story is worth pausing on. Costco got $184 million back in Q4 — that's about a third of what they expect total — and instead of just banking it, they plowed a chunk of it back into member value. Price cuts on everyday stuff: produce, meat, beverages, even home furnishings and hardware. JORDAN: Which is very on-brand for Costco. CEO Ron Vachris basically said it outright — when they see lower prices, they see an opportunity. And it's not just talk; they're planning to keep reinvesting the majority of future tariff refunds the same way into fiscal 2027. ALEX: Let's talk membership, because that's always the metric everyone obsesses over. Executive members hit an all-time high — 42.3 million, up 9.4% year over year. Total paid membership was 84.1 million, up 3.8%. JORDAN: But an analyst on the call — Scot Ciccarelli from Truist — pushed on this pretty hard. Membership growth has been slowing for eight straight quarters. Gary's answer was essentially: this is more of a normalization than a red flag. New sign-ups are still growing, renewal rates ticked up to 92.3% in the U.S. and Canada, and the real story is quality over raw headcount — more executive members, more gas engagement, more digital engagement, all of which correlate with higher spend and stickier loyalty. ALEX: The under-40 member cohort is a big part of that story too. It's grown nearly 60% since COVID and now makes up more than a quarter of Costco's total membership base. They spend less initially, but the expectation is they mature into higher-value members over time. JORDAN: Now, on the ancillary business side — gas, pharmacy, and travel were the real stars. Gas had a record year, with comps up in the mid-30s, and Costco says it saved members over $3.2 billion at the pump versus market average pricing. ALEX: Pharmacy grew nearly 20%, even absorbing headwinds from Medicare pricing changes on drugs, partly thanks to GLP-1 programs and their fertility program driving double-digit script growth. And travel — vacation packages, cruises, car rentals — all grew double digits. There was this incredible anecdote about a member booking a 154-night cruise for over $218,000 and getting an $8,800 shop card back. JORDAN: That's a wild flex for what's supposed to be a value retailer, but it kind of shows the range Costco's operating in right now — from Kirkland walnuts down four bucks a bag to six-figure cruise bookings. ALEX: Let's touch on digital, because there wa This episode includes AI-generated content.

  ListenShow Notes
• 

  Beta Finch - S&P 100 - EN

  Zoetis Q2 2026 Earnings Analysis

  Sep 16, 20268 min

  More earnings analysis: https://betafinch.com Groups: PHARMA ( https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex. JORDAN: And I'm Jordan. Today we're diving into Zoetis, ticker ZTS, the animal health giant. Q2 2026 results, and Alex, this one's a bit of a bumpy ride. ALEX: It really is. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good to have that out front. So let's set the scene. Zoetis reported second quarter revenue of $2.5 billion — flat on a reported basis, actually down 1% organically. Adjusted net income came in at $781 million, down 2% organically. And here's the headline: they cut full-year guidance. ALEX: Yeah, this wasn't a small tweak either. New revenue guidance is $9.12 to $9.32 billion, which works out to a decline of 3% to 1% for the year. Adjusted net income guidance dropped to a range implying a decline of 9% to 5%. That's a meaningful reset. JORDAN: So what happened? Basically, the U.S. Companion Animal business — think dogs and cats, not cattle and chickens — got hit hard. Revenue there was down 11% in the U.S. Fewer vet visits, pet owners being more price-conscious, and a lot more competitors piling into categories Zoetis basically invented, like dermatology treatments. ALEX: Right, and that's the key tension here. Their blockbuster drug Apoquel and the whole Key Dermatology franchise — U.S. dermatology revenue was down 18% in the quarter. New competitors are using aggressive discounting and rebates to steal share, and it's not growing the overall market, it's just splitting up a shrinking pie. JORDAN: Even so, Zoetis still holds about 86% in-clinic share in U.S. dermatology, even after losing 10 points year-over-year. So they're still dominant, just under real pressure for the first time in a while. ALEX: And parasiticides — flea, tick, heartworm meds like Simparica — were basically flat globally, with the U.S. side down 6%. Management said it's less about a specific competitor and more about a broader pullback in vet visits. JORDAN: But here's the plot twist — it's not all bad news. Livestock had a phenomenal quarter, up 11% globally, and 23% in the U.S., partly boosted by demand for cattle parasiticides tied to that New World screwworm outbreak. And Diagnostics grew 12%, driven by point-of-care testing demand. ALEX: So basically, the pet side is struggling, but the farm animal side and the diagnostics side are picking up a lot of the slack. JORDAN: Exactly — that diversification is doing real work for them right now. ALEX: Let's talk strategy, because CEO Kristin Peck was pretty clear about their playbook. Instead of cutting list prices — which she called a "permanent structural change" — they're doing what's called gross-to-net investment. Basically targeted rebates, promotions, and bundling deals to protect market share without blowing up their pricing structure long-term. JORDAN: It's a defend-the-fort strategy. Protect volume and share now, keep the sticker price intact, and hope the competitive intensity eases once the market sorts itself out. CFO Wetteny Joseph said full-year price realization could land anywhere from flat to down 2%, depending on how aggressive they need to get. ALEX: There's also a leadership shakeup worth mentioning. Wetteny Joseph, the CFO, is stepping down after five years — a new hire, Jay Saccaro, is coming in not just as CFO but in a newly created combined CFO and Chief Operating Officer role, overseeing manufacturing and supply chain too. That's a pretty significant restructuring of the C-suite, aimed at s This episode includes AI-generated content.

  ListenShow Notes
• 

  Beta Finch - S&P 100 - EN

  Zoetis Q1 2026 Earnings Analysis

  Sep 16, 20268 min

  More earnings analysis: https://betafinch.com Groups: PHARMA ( https://betafinch.com/groups/PHARMA) ────────── # Beta Finch Podcast Script: Zoetis Q1 2026 Earnings **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results to help you understand what's really happening in the market. I'm Alex. **JORDAN:** And I'm Jordan. Before we dig in, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **ALEX:** Today we're breaking down Zoetis' Q1 2026 earnings - and wow, this was a quarter that really caught investors off guard. Jordan, what's your first take on these numbers? **JORDAN:** Alex, this was definitely a reality check for the animal health giant. On the surface, flat organic operational revenue growth doesn't look terrible, but when you peel back the layers, there's a lot more going on here. They had about $100 million in sales that shifted from Q4 2025 into Q1 due to fiscal year alignment changes. Without that boost, they would have seen a 5% organic operational decline. **ALEX:** That's a significant difference. And CEO Kristin Peck was pretty candid about what went wrong, wasn't she? **JORDAN:** Absolutely. She laid out four key factors that created what she called "a convergence of interconnected dynamics." First, rising prices at veterinary clinics led to lower clinic traffic - pet owners are feeling the pinch. Second, those same pet owners are showing increased price sensitivity, especially for premium products where Zoetis leads. Third, competition intensified across key categories like dermatology and parasiticides, with competitors using aggressive pricing. And fourth - this is crucial - these competitive launches didn't expand the overall market like they have historically. **ALEX:** That last point seems really important. Historically, when new competitors entered Zoetis markets, the pie got bigger for everyone. But not this time? **JORDAN:** Exactly. In the past, competition actually helped grow markets - think about how the parasiticide market expanded when new players came in. But this time, with pet owners being more price-conscious and visiting clinics less frequently, new entrants are just taking share from existing players rather than bringing new customers into the market. **ALEX:** Let's talk specific numbers. How did their key franchises perform? **JORDAN:** The companion animal business really struggled, particularly in the U.S. where it declined 11%. Their key dermatology franchise - which includes blockbusters like Apoquel and Cytopoint - fell 11% globally to $347 million. The Simparica parasiticide franchise was down 1% to $385 million globally, but that masks an 8% decline in the U.S. And their OA Pain products, Librela and Solensia, dropped 8% combined to $140 million. **ALEX:** But it wasn't all bad news, right? I noticed livestock performed well. **JORDAN:** That's the silver lining here. Livestock delivered 12% organic operational growth to $720 million, with broad-based strength across cattle, poultry, and swine. Favorable producer economics and strong protein demand are driving investment in herd health. It really shows the value of Zoetis' diversified portfolio - when companion animal struggles, livestock can pick up some slack. **ALEX:** What about guidance? I imagine they had to adjust expectations. **JORDAN:** They definitely had to recalibrate. Full-year revenue growth guidance came down to 2-5% from what was presumably higher expectations, and adjusted net income growth is now expected at 2-6%. CFO Wetteny Joseph noted that while the fiscal year alignment was supposed to provide a 200-250 basis point tailwind, the challenging operating environment more than offset that benefit. **ALEX:** During the Q&A, there were some pointe This episode includes AI-generated content.

  ListenShow Notes
• 

  Beta Finch - S&P 100 - EN

  Zoetis Q4 2025 Earnings Analysis

  Sep 16, 20269 min

  More earnings analysis: https://betafinch.com Groups: PHARMA ( https://betafinch.com/groups/PHARMA) ────────── **BETA FINCH PODCAST SCRIPT** --- ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that move markets. I'm Alex, and I'm here with my co-host Jordan to dive into Zoetis' Q4 2025 earnings call. Jordan, this was quite the earnings report from the animal health giant. JORDAN: Absolutely, Alex. But before we jump into the numbers, I need to share an important disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. ALEX: Thanks for that, Jordan. Now, let's talk Zoetis. The company reported some solid numbers for 2025 - $9.5 billion in revenue with 6% organic operational growth, and adjusted net income growing 7% organically. They hit the high end of their November guidance range. JORDAN: That's right, and what I found particularly interesting is how their international markets really carried the load here. International delivered 8% organic operational revenue growth while the U.S. was at 4%. It really shows the value of having that global diversification, especially when you're dealing with some headwinds in your home market. ALEX: Speaking of headwinds, CEO Kristin Peck was pretty candid about what they're seeing in the U.S. veterinary market. She mentioned economic pressure on Gen Z and millennial pet owners, which has led to declining therapeutic visits. But here's the fascinating part - emergency and urgent care are still showing strength. JORDAN: That's such an important distinction, Alex. It's not that pet owners love their animals any less or that underlying demand for care is declining. It's more about price sensitivity and tighter household budgets when it comes to routine care. Pet owners are still bringing their dogs in when they're sick, but they're being more selective about wellness visits. ALEX: Exactly. And Peck mentioned that clinics are starting to react by taking a more measured approach to the overall cost of care. The company is responding with targeted actions - optimizing their channel mix, increasing outreach to veterinarians, and reinforcing their scientific leadership through expanded medical education. JORDAN: Let's talk about their star performer - the Simparica franchise. This is really impressive stuff. The franchise grew 12% operationally for the year, with Simparica Trio hitting over $1 billion in U.S. sales alone. That makes it their first brand to cross that billion-dollar threshold in the U.S. ALEX: And globally, Trio maintained its position as the number one selling canine brand. What I found interesting is their omnichannel strategy - they're seeing double-digit contributions from retail and home delivery channels, which is helping them navigate those headwinds in traditional veterinary clinics. JORDAN: That's smart positioning. They're essentially meeting customers where they want to shop, whether that's at the vet, at retail, or having products delivered to their home. It's all about convenience and compliance for pet owners. ALEX: Now, let's address the elephant in the room - their OA pain franchise. This declined 3% operationally, with Librela specifically down 6%. This has been a challenge for Zoetis, and there have been some safety concerns raised about these monoclonal antibody treatments. JORDAN: Right, but Peck seemed confident about their multipronged strategy to turn this around. She mentioned they're seeing stabilizing monthly sales trends and that veterinarian and pet owner satisfaction remains high. Plus, they're introducing new products like Lanivia and Portela to expand their OA pain portfolio. ALEX: The guidance for 2026 is what really caught my attention, Jordan. They're projecting 3% to 5% organic operatio This episode includes AI-generated content.

  ListenShow Notes
• 

  Beta Finch - S&P 100 - EN

  Exxon Mobil Q1 2026 Earnings Analysis

  Sep 16, 20267 min

  More earnings analysis: https://betafinch.com Groups: ENERGY ( https://betafinch.com/groups/ENERGY) ────────── **BETA FINCH PODCAST SCRIPT** --- **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Exxon Mobil's Q1 2026 earnings call - and wow, what a quarter to unpack. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN**: Thanks Alex. And right off the bat, we need to address the elephant in the room - this earnings call was dominated by the ongoing Middle East conflict and its impact on global energy markets. CEO Darren Woods opened with some pretty sobering commentary about the situation. **ALEX**: Absolutely. Woods was very direct about the human cost first, mentioning their colleagues and partners living under daily threats in the region. But from a business perspective, Jordan, the disruption has actually highlighted Exxon's competitive advantages in a major way. **JORDAN**: Exactly. What struck me was how Woods framed this as essentially a stress test for all the changes they've made over the past decade. And by most measures, they seem to have passed with flying colors. Despite what he called "unprecedented disruption in the world supply of oil and natural gas," they maintained deliveries globally and even ramped up refining production by 200,000 barrels per day from February to March. **ALEX**: That's like adding a mid-sized refinery overnight! And the financial results reflect this operational excellence. Even excluding timing effects and identified items, their first-quarter earnings per share were up versus 2025. CFO Kathy Mikells highlighted that their Energy Products segment made $2.8 billion in the quarter - that's up $2 billion from last year. **JORDAN**: The refining story is particularly compelling. Remember when Exxon announced that Beaumont refinery expansion back in 2023? There were lots of questions about whether refining investments made sense. Well, Woods announced that expansion has already fully recovered its initial investment - ahead of expectations. **ALEX**: And they're not just benefiting from higher margins - they're creating structural advantages. Their Gulf Coast refineries ran at record utilization rates, and they've got this global supply chain organization that rapidly executed alternate routings from the US Gulf Coast to Asia. It's that scale and integration advantage Woods keeps talking about. **JORDAN**: Speaking of scale advantages, let's talk about their growth engines. In Guyana, they hit record production levels again and have three new projects under construction. The Oahu project expects first oil late this year. But what I found interesting was their $100 million commitment over ten years for STEM education in Guyana - that's the kind of long-term relationship building that creates sustainable competitive advantages. **ALEX**: And in the Permian, they're still on track for 1.8 million oil-equivalent barrels this year, with that longer-term target of 2.5 million. What's interesting is Woods' confidence that they're not seeing any plateau in opportunities there, unlike some competitors who've predicted resource constraints. **JORDAN**: The LNG story is fascinating too. Golden Pass achieved first LNG in March - that's about a 5% increase in US LNG exports. And by the time all three trains are online, they'll increase current US exports by roughly 15%. But here's what's really notable - with the Middle East disruptions, that "long" LNG market everyone was predicting has essentially disappeared overnight. **ALEX**: Right, and they've got Papua New Guinea and Mozambique LNG projects expecting final investment decisions later this year. Woods was pretty confident about their position This episode includes AI-generated content.

  ListenShow Notes

Recent guests on Beta Finch - S&P 100 - EN. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.